Soluble cd30: A possible serum tumor marker for primary effusion lymphoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 4939-4941

  Michai, Manthana ^a,b   Goto, Hiroki ^a   Hattori, Shinichiro ^a   Vaeteewoottacharn, Kulthida ^a,c   Wongkham, Chaisiri ^c   Wongkham, Sopit ^c   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KHON KAEN HOSPITAL   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

HIV 1; Malignant lymphoma; Primary effusion lymphoma; Soluble CD30; Tumor marker

Indexed keywords

EID: 84874002517     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.4939     Document Type: Article

References (18)

1. Al-Shamkhani A (2004). The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol, 4, 355-9.
2. Ambinder RF, Bhatia K, Martinez-Maza O, et al (2010). Cancer biomarkers in HIV patients. Curr Opin HIV AIDS, 5, 531-7.
3. Breen EC, Fatahi S, Epeldegui M, et al (2006). Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol, 27, 187-94.
4. Chen YB, Rahemtullah A, Hochberg E (2007). Primary effusion lymphoma. Oncol, 12, 569-76.
5. Drexler HG, Uphoff CC, Gaidano G, et al (1998). Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia, 12, 1507-17.
6. Higuchi M, Matsuda T, Mori N, et al (2005). Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation. Retrovirology, 2, 29.
7. Horie R, Watanabe T (1998). CD30: expression and function in health and disease. Semin Immunol, 10, 457-70.
8. Jarrin I, Boval B, Mazeron MC, et al (2011). Can serum soluble CD23 OR CD30 predict the occurence of lymphoma in HIV-infected patients? J Acquir Immune Defic Syndr, 57, 58-61.
9. Katano H, Hoshino Y, Morishita Y, et al (1999). Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. J Med Virol, 58, 394-401.
10. Miyagi J, Masuda M, Takasu N, et al (2002). Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice. Int J Hematol, 76, 165-72.
11. Nadali G, Vinante F, Ambrosetti A, et al (1994). Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol, 12, 793-7.
12. Nadali G, Vinante F, Stein H, et al (1995). Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. J Clin Oncol, 13, 1355-60.
13. Nador RG, Cesarman E, Chadburn A, et al (1996). Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood, 88, 645-56.
14. Nagai H, Iwasaki N, Odawara T, et al (2008). Actual status of AIDS-related lymphoma management in Japan. Int J Hematol, 87, 442-3.
15. Nishioka C, Takemoto S, Kataoka S, et al (2005). Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma. Cancer Sci, 96, 810-5.
16. Purdue MP, Lan Q, Martinez-Maza O, et al (2009). A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood, 114, 2730-2.
17. Vermeulen R, Hosnijeh FS, Portengen L, et al (2011). Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev, 20, 1925-7.
18. Visco C, Nadali G, Vassilakopoulos TP, et al (2006). Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol, 77, 387-94.